Alterity Therapeutics

<div class="ih-global-ui-overrides"></div>
<style>
  /* ==========================================================================
     InvestorHub Global UI Overrides
     Prefix: ih-
     Purpose:
       1) Hide share price / ticker widget
       2) Hide survey launcher button
       3) Hide injected timed survey popup panel
     ========================================================================== */
  /* --------------------------------------------------------------------------
     1) Hide ASX ticker / share price widget
     -------------------------------------------------------------------------- */
  #share-price {
    display: none !important;
    visibility: hidden !important;
    width: 0 !important;
    height: 0 !important;
    overflow: hidden !important;
  }
  #share-price + .h-8.w-px.bg-hubs-dividers {
    display: none !important;
  }
  /* --------------------------------------------------------------------------
     2) Hide the floating survey launcher button (bottom-right)
     (your earlier snippet)
     -------------------------------------------------------------------------- */
  .fixed.right-2.bottom-2.z-20.rounded-full.shadow-lg,
  .fixed.right-2.bottom-2.z-20 {
    display: none !important;
    visibility: hidden !important;
    pointer-events: none !important;
  }
  /* --------------------------------------------------------------------------
     3) Hide the timed/injected survey popup panel
     (the wrapper you pasted)
     -------------------------------------------------------------------------- */
  /* Extremely specific: matches the exact utility-class signature of that popup */
  .fixed.right-0.bottom-24.z-30.overflow-hidden.rounded-xl.shadow-xl.sm\:right-4.md\:bottom-4 {
    display: none !important;
    visibility: hidden !important;
    pointer-events: none !important;
  }
  /* Slightly more flexible fallback (in case spacing classes change later)
     Still specific enough to avoid collateral damage */
  .fixed.z-30.overflow-hidden.rounded-xl.shadow-xl.bottom-24 {
    display: none !important;
    visibility: hidden !important;
    pointer-events: none !important;
  }
  /* Optional: if it ever mounts but stays in DOM, ensure it can't capture clicks */
  .fixed.z-30.overflow-hidden.rounded-xl.shadow-xl.bottom-24 * {
    pointer-events: none !important;
  }
</style>

<script>
  /* ==========================================================================
     InvestorHub Global UI Overrides
     Prefix: ih-
     Purpose:
       Rewrite the "Privacy Policy" link used by the cookie consent banner and
       the subscriber sign-up popup away from the InvestorHub microsite policy
       and onto Alterity Therapeutics' own privacy policy page.
       Does not touch the Terms and Conditions link or anything else.
     ========================================================================== */
  (function () {
    var OLD_PRIVACY_URL = 'https://investorhub.com/au-microsite-privacy-policy';
    var NEW_PRIVACY_URL = 'https://alteritytx.com/privacy-policy';
    function fixPrivacyLinks(root) {
      if (!root || !root.querySelectorAll) return;
      var links = root.querySelectorAll('a[href="' + OLD_PRIVACY_URL + '"]');
      for (var i = 0; i < links.length; i++) {
        links[i].setAttribute('href', NEW_PRIVACY_URL);
      }
    }
    // Catch links already present at load time.
    if (document.readyState === 'loading') {
      document.addEventListener('DOMContentLoaded', function () {
        fixPrivacyLinks(document);
      });
    } else {
      fixPrivacyLinks(document);
    }
    // The cookie banner and subscriber popup mount client-side after hydration
    // (and can remount on client-side route changes), so watch for them.
    var observer = new MutationObserver(function (mutations) {
      for (var m = 0; m < mutations.length; m++) {
        var addedNodes = mutations[m].addedNodes;
        for (var n = 0; n < addedNodes.length; n++) {
          var node = addedNodes[n];
          if (node.nodeType !== 1) continue;
          if (node.matches && node.matches('a[href="' + OLD_PRIVACY_URL + '"]')) {
            node.setAttribute('href', NEW_PRIVACY_URL);
          }
          fixPrivacyLinks(node);
        }
      }
    });
    observer.observe(document.documentElement || document.body, {
      childList: true,
      subtree: true
    });
  })();
</script>



<style>
  /* A. Desktop sidebar survey card.
        Anchored to #lg-announcement-comments-section, so it cannot escape the
        sidebar rail. The Q&A card is the other child and is unaffected: it uses
        the chat-bubble icon, not this one. */
  #lg-announcement-comments-section > div.rounded-lg:has(> div > button.group svg path[d^="M9 12h3.75M9 15h3.75"]) {
    display: none !important;
  }
  /* B. Mobile PDF toolbar: hide ONLY the feedback button, never the toolbar.
        Scoped to the toolbar's own class signature so the PDF wrapper above it
        is never in scope. */
  div.fixed.right-3.left-3.z-10 > button:has(svg path[d^="M9 12h3.75M9 15h3.75"]) {
    display: none !important;
  }
</style>
<script>
  (function () {
    if (window.__ihSurveyHider) return;
    window.__ihSurveyHider = true;
    var HEADING = 'share your feedback';
    /* Hard stop list. If a candidate contains any of these we are too far up. */
    var PROTECTED = '.react-pdf__Document, #interactive-pdf, #annotation-toolbar, canvas, iframe, embed, object, video';
    function hide(el) {
      if (el) el.style.setProperty('display', 'none', 'important');
    }
    function isHidden(el) {
      if (!el || el.nodeType !== 1) return true;
      if (/display:\s*none/.test(el.getAttribute('style') || '')) return true;
      return window.getComputedStyle(el).display === 'none';
    }
    function safeToHide(el) {
      if (!el) return false;
      if (el === document.body || el === document.documentElement) return false;
      if (['MAIN', 'HEADER', 'FOOTER'].indexOf(el.tagName) > -1) return false;
      if (el.querySelector('#question-section')) return false;
      if (el.querySelector(PROTECTED)) return false;
      return true;
    }
    function sweep() {
      document.querySelectorAll('p').forEach(function (el) {
        if ((el.textContent || '').replace(/\s+/g, ' ').trim().toLowerCase() !== HEADING) return;
        /* Desktop sidebar card. Hidden inline (not just by stylesheet) so the
           rail-collapse check below and in your Q&A script both see it. */
        var card = el.closest('.rounded-lg.bg-hubs-background-accent');
        if (card && safeToHide(card)) { hide(card); return; }
        /* Mobile bottom sheet (rounded-t-2xl, so the rule above misses it). */
        var sheet = el.closest('.fixed.bottom-0');
        if (sheet && safeToHide(sheet)) hide(sheet);
      });
      /* Mobile PDF toolbar button, JS-side mirror of rule B. Hides the button
         only -- the toolbar keeps its page controls and download. */
      document.querySelectorAll('div.fixed.right-3.left-3 > button').forEach(function (btn) {
        var p = btn.querySelector('svg path');
        if (p && (p.getAttribute('d') || '').indexOf('M9 12h3.75M9 15h3.75') === 0) hide(btn);
      });
      /* Collapse the desktop rail only if both cards are now gone. Deliberately
         scoped to the lg- section: the sm- sheets are fixed overlays whose
         parents hold unrelated content. "Discover" is a sibling of this
         wrapper inside #announcement-sidebar, so it survives. */
      var section = document.getElementById('lg-announcement-comments-section');
      if (!section) return;
      var hasVisible = Array.prototype.some.call(section.children, function (child) {
        return !isHidden(child);
      });
      if (hasVisible) return;
      hide(section);
      var parent = section.parentElement;
      if (parent && parent.children.length === 1 && safeToHide(parent)) hide(parent);
    }
    var pending = false;
    function queueSweep() {
      if (pending) return;
      pending = true;
      requestAnimationFrame(function () { pending = false; sweep(); });
    }
    function start() {
      sweep();
      new MutationObserver(queueSweep).observe(document.body, { childList: true, subtree: true });
    }
    if (document.body) { start(); }
    else { document.addEventListener('DOMContentLoaded', start); }
  })();
</script>

<style>
  /* ==========================================================================
     InvestorHub Global UI Overrides
     Prefix: ih-
     Purpose:
       Give the announcement / PDF column more room on desktop by narrowing the
       right-hand sidebar rail and widening the overall page container. The rail
       holds the survey card (already hidden above), the Q&A / question box and
       "Discover more" -- all three are forced to follow the narrower rail width
       rather than holding their own fixed or minimum width. The annotation
       toolbar is nudged to stay clear of the narrowed rail.
       Desktop only (>=1024px) so mobile layout is untouched.
     ========================================================================== */
  @media (min-width: 1024px) {
    /* The rail itself. flex-basis is set as well as width because the rail is a
       flex child -- width alone can be ignored if a basis is already declared. */
    #announcement-sidebar {
      width: 400px !important;
      max-width: 400px !important;
      flex: 0 0 400px !important;
    }
    /* The page container that holds the announcement + the rail. */
    div:has(> #announcement-sidebar) {
      max-width: 1712px !important;
    }
    /* Everything inside the rail: Q&A / question box, the comments wrapper and
       "Discover more". Clears any fixed or min-width so they shrink with the
       rail instead of overflowing it. */
    #announcement-sidebar > *,
    #lg-announcement-comments-section,
    #lg-announcement-comments-section > *,
    #question-section {
      width: auto !important;
      max-width: 100% !important;
      min-width: 0 !important;
    }
    /* Keep the PDF annotation toolbar clear of the narrowed rail (400 + 64px
       gutter). Adjust this one number if the gap looks off. */
    #annotation-toolbar {
      right: 464px !important;
    }
  }
</style>

Home

Team

About Us

About Us Overview

Pipeline

Parkinsonian Diseases

Multiple System Atrophy

ATH434

Publications & Presentations

The Science

Analyst Coverage

Share Price

Events and Presentations

Announcements

Press Releases 2026

Investor Overview

Governance

Investors

Synapse Sessions

In The News

Media

Contact Us

Montserrat

Alterity Therapeutics Receives a $4.74 million Research & Development Tax
Incentive Refund
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 August 2023. Alterity Therapeutics Limited
(ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to
developing disease modifying treatments for neurodegenerative diseases, today announced that it has
received a A$4.74 million cash refund from the Australian Taxation Office under the Australian
Government’s Research and Development Tax Incentive (R&DTI) Scheme.
The cash refund relates to the cost of eligible research and development activities conducted during the
financial year ended 30 June 2022, and represents the amount disclosed in the company’s audited
financial statements. These funds will be used to further Alterity’s clinical development and research
activities, including the ongoing Phase 2 clinical trials for the Company’s lead drug candidate ATH434 in
Multiple System Atrophy (MSA), a Parkinsonian disorder with no approved therapy.
About ATH434
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological
proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein
pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it
has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as
Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent
is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA.
ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind,
placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an
open-label Phase 2 Biomarker trial in patients with MSA. ATH434 has been granted Orphan drug
designation for the treatment of MSA by the U.S. FDA and the European Commission.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future
for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential
to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in
Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable
chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in
Melbourne, Australia, and San Francisco, California, USA. For further information please visit the
Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

Alterity receives a $4.74 million R&D Tax Refund